Cazepsin stabilises hyperexcited nerve membranes, inhibits repetitive neuronal discharges, and reduces synaptic propagation of excitatory impulses. It is conceivable that prevention of repetitive firing of sodium-dependent action potentials in depolarised neurons via use- and voltage-dependent blockade of sodium channels may be its main mechanism of action.
Each uncoated tablet contains :
Carbamazepine BP 200 mg.
For oral use
Epilepsy:
Adults and children over 12 years of age –
Initial: Either 200 mg b.i.d. for tablets (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d. regimen of Carbamazepine or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: Adjust dosage to the minimum effective level, usually 800-1200 mg daily.
Children 6-12 years of age:
Initial: Either 100 mg b.i.d. for tablets. Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. regimen of Carbamazepine or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily.
Maintenance: Adjust dosage to the minimum effective level, usually 400-800 mg.
Children under 6 years of age:
Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of carbamazepine for use at doses above 35 mg/kg/24 hours can be made.
Each uncoated tablet contains :
Carbamazepine BP 200 mg.
For oral use
Epilepsy:
Adults and children over 12 years of age –
Initial: Either 200 mg b.i.d. for tablets (400 mg/day). Increase at weekly intervals by adding up to 200 mg/day using a b.i.d. regimen of Carbamazepine or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily in children 12-15 years of age, and 1200 mg daily in patients above 15 years of age. Doses up to 1600 mg daily have been used in adults in rare instances. Maintenance: Adjust dosage to the minimum effective level, usually 800-1200 mg daily.
Children 6-12 years of age:
Initial: Either 100 mg b.i.d. for tablets. Increase at weekly intervals by adding up to 100 mg/day using a b.i.d. regimen of Carbamazepine or a t.i.d. or q.i.d. regimen of the other formulations until the optimal response is obtained. Dosage generally should not exceed 1000 mg daily.
Maintenance: Adjust dosage to the minimum effective level, usually 400-800 mg.
Children under 6 years of age:
Initial: 10-20 mg/kg/day b.i.d. or t.i.d. as tablets. Increase weekly to achieve optimal clinical response administered t.i.d. or q.i.d. Maintenance: Ordinarily, optimal clinical response is achieved at daily doses below 35 mg/kg. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the therapeutic range. No recommendation regarding the safety of carbamazepine for use at doses above 35 mg/kg/24 hours can be made.